Log in to save to my catalogue

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and imm...

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and imm...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604731

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

About this item

Full title

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Publisher

New York: Nature Publishing Group US

Journal title

Nature medicine, 2021-11, Vol.27 (11), p.1910-1920

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval of combination immune checkpoint blockade. Here we report the results of the phase 2 PrE0505 trial (
NCT02899195
) of the anti-PD-L1 antibody durvalumab plus platinum-pemetrexed chemotherapy for 55 patients with previously untreated, unresectabl...

Alternative Titles

Full title

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604731

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604731

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/s41591-021-01541-0

How to access this item